PP2
| Code | Size | Price |
|---|
| AG-CR1-3563-M001 | 1 mg | £50.00 |
Quantity:
| AG-CR1-3563-M005 | 5 mg | £170.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
4-Amino-5-(4-chlorophenyl)-7-(tert.butyl)pyrazolo-(3,4-d)pyrimidine; AG 1879
Appearance:
White solid.
CAS:
172889-27-9
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Hazards:
H302
InChi:
InChI=1S/C15H16ClN5/c1-15(2,3)21-14-11(13(17)18-8-19-14)12(20-21)9-4-6-10(16)7-5-9/h4-8H,1-3H3,(H2,17,18,19)
InChiKey:
PBBRWFOVCUAONR-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 172889-27-9. Formula: C15H16ClN5. MW: 301.8. Highly potent and selective Scr family tyrosine kinase inhibitor. Reduces cancer metastasis. Apoptotic. Antitumor compound. RIP2 inhbitor. Blocks TGF-beta-mediated cellular responses. Autophagy modulator.
MDL:
MFCD01568210
Molecular Formula:
C15H16ClN5
Molecular Weight:
301.8
Package Type:
Vial
Precautions:
P270, P301, P312, P330
Product Description:
Highly potent and selective Scr family tyrosine kinase inhibitor [1, 4, 6]. Reduces cancer metastasis [2]. Apoptotic [5]. Antitumor compound [2, 3, 5]. RIP2 inhbitor [6]. Blocks TGF-beta-mediated cellular responses [7]. Autophagy modulator [8].
Purity:
>98% (HPLC)
Signal word:
Warning
SMILES:
CC(C)(C)N1N=C(C2=C1N=CN=C2N)C1=CC=C(Cl)C=C1
Solubility Chemicals:
Soluble in DMSO. Slightly soluble in ethanol.
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.
References
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996) | Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis: J.S. Nam, et al.; Clin. Cancer Res. 8, 2430 (2002) | Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2): F. Carlomagno, et al.; J. Clin. Endocrinol. Metab. 88, 1897 (2003) | The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003) | Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia: M. Lee, et al.; J. Cell Biochem. 93, 629 (2004) | The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007) | The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011) | Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2: J.H. Ahn & M. Lee; Cancer Lett. 310, 188 (2011)
Related Products
| Product Name | Product Code | Supplier | PP1 | AG-CR1-3562 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|